New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:21 EDTHZNPHorizon Pharma to host special shareholder meeting
Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.
September 15, 2014
08:12 EDTHZNPHorizon Pharma valuation at attractive entry point, says Cowen
Subscribe for More Information
September 9, 2014
10:09 EDTHZNPHorizon Pharma initiated with an Outperform at Avondale (pre-open)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use